Abstract #1899

T1 Mapping for Immunotherapy in Head and Neck Squamous Cell Carcinoma

Jiangming Qu¹, Tong Su¹, Yu Chen¹, Zhentan Xu¹, Tianjiao Wang¹, Jinxia Zhu², Xiaoye Wang², Haihong Fu¹, Zhuhua Zhang¹, Feng Feng¹, and Zhengyu Jin¹

¹Department of Radiology, Peking Union Medical College Hospital, Chinese Acadamy of Medical Sciences, Beijing, China, ²MR Research Collaboration, Siemens Healthineers Ltd., Beijing, China

Synopsis

Keywords: Head & Neck/ENT, Head & Neck/ENT, T1 mapping

Motivation: Patients with head and neck squamous cell carcinoma (HNSCC) are at high risk for recurrence and metastasis; however, predicting patients who will be sensitive to immunotherapy can be difficult.

Goal(s): We aimed to determine whether T1 mapping could help in selecting patients and predicting immunotherapeutic efficacy for patients with HNSCC.

Approach: We retrospectively analyzed the results from HNSCC patients who underwent pretreatment T1 mapping. PD-L1 expression were evaluated by immunohistochemistry. Patients who received immunotherapy were then classified as responders or non-responders.

Results: T1 values showed predictive value for prediction of PD-L1expression and assessing response to immunotherapy in HNSCC.

Impact: T1 mapping can help to guide treatment decisions in the context of immunotherapy in HNSCC.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.